We are live on ! Find out more
VBIV

VBI Vaccines, Inc. New Common Stock (Canada)
VBIV

Delisted

VBIV was delisted on the 7th of August, 2024.

Back to rankings

36 hedge funds and large institutions have $1.61M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less capital invested

Capital invested by funds: $1.71M → $1.61M (-$96.1K)

8% less funds holding

Funds holding: 39 → 36 (-3)

42% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 12

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
36
Holders Change
-3
Holders Change %
-7.69%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
7
Reduced
12
Closed
3
Calls
$484K
Puts
–
Net Calls
+$484K
Net Calls Change
-$47K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$3K
2
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
+$2.15K
3
WIA
Wetzel Investment Advisors
Indiana
+$1.23K
4
Goldman Sachs
Goldman Sachs
New York
+$506
5
Wells Fargo
Wells Fargo
California
+$96

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$73.3K
2
Citadel Advisors
Citadel Advisors
Florida
-$40.2K
3
TSS
Two Sigma Securities
New York
-$14.4K
4
Renaissance Technologies
Renaissance Technologies
New York
-$5.82K
5
Millennium Management
Millennium Management
New York
-$3.31K

VBIV Hedge Fund Activity: Q1 2024 in Review

36 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q1 2024, worth a combined $1.61M — down 5.6% from $1.71M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of VBIV and 1 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 7 added.

The largest buyer was Geode Capital Management, adding an estimated $3K. The largest seller was Perceptive Advisors, cutting an estimated $73.3K.

  • 36 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q1 2024, down from 39 in Q4 2023.
  • Funds reported $1.61M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q1 2024, down 5.6% quarter-over-quarter.
  • 1 fund opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q1 2024 and 3 closed out, a net change of -2 holders.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q1 2024 was Geode Capital Management, an estimated $3K added.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q1 2024 was Perceptive Advisors, an estimated $73.3K sold.

Based on aggregated 13F filings for Q1 2024.